echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > U.S. FDA approves Gilead's low-dose Biktarvy for use in young HIV-1 children

    U.S. FDA approves Gilead's low-dose Biktarvy for use in young HIV-1 children

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gilead Sciences recently announced that the U.


    Although effective treatment options available to pregnant women infected with HIV reduce the possibility of transmission of HIV infection during the perinatal period, pediatric HIV remains a global health problem


    The FDA approved Biktarvy for HIV-1 infection in children weighing at least 14 kg, based on data from cohort 3 of the Phase 2/3 open-label single-arm study (NCT02881320)


    Biktarvy is a single-tablet regimen (STR) taken orally once a day for the treatment of HIV-1 infection


    In the United States, Biktarvy was approved for marketing in February 2018.


    In China, Biktarvy was approved in Hong Kong in October 2018 and approved in the Mainland in August 2019


    Note: The original text has been deleted

    Original source: US Food and Drug Administration Approves Expanded Indication of Gilead's Biktarvy® for Treatment of HIV-1 in Pediatric Populations

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.